Patents by Inventor Rejean Fortin

Rejean Fortin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apparatus for quenching
    Patent number: 10316378
    Abstract: A quenching agent delivery apparatus is provided for delivering a quenching agent to a component to be quenched. The delivery apparatus comprises an inlet through which the quenching agent is configured to be delivered into the apparatus, a first outlet configured to deliver quenching agent in a first direction to an inner surface of the component, and a second outlet configured to deliver quenching agent in a second direction to an inner surface of the component.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 11, 2019
    Assignees: Safran Landing Systems Canada Inc., Safran Landing Systems UK LTD
    Inventors: Rejean Fortin, Yachoa Wang, Abdallah Boukhchacha
  • APPARATUS FOR QUENCHING
    Publication number: 20160237516
    Abstract: A quenching agent delivery apparatus is provided for delivering a quenching agent to a component to be quenched. The delivery apparatus comprises an inlet through which the quenching agent is configured to be delivered into the apparatus, a first outlet configured to deliver quenching agent in a first direction to an inner surface of the component, and a second outlet configured to deliver quenching agent in a second direction to an inner surface of the component.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 18, 2016
    Inventors: Rejean Fortin, Yachoa Wang, Abdallah Boukhchacha
  • Renin inhibitors
    Patent number: 8334308
    Abstract: The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 18, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Rejean Fortin, Patrick Lacombe, Daniel McKay, Tom Yao-Hsiang Wu
  • RENIN INHIBITORS
    Publication number: 20110263658
    Abstract: The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: August 18, 2008
    Publication date: October 27, 2011
    Inventors: Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Rejean Fortin, Patrick Lacombe, Daniel McKay, Tom Yao-Hsiang Wu
  • SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY
    Publication number: 20100298347
    Abstract: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.
    Type: Application
    Filed: December 1, 2008
    Publication date: November 25, 2010
    Applicant: MERCK FROSST CANADA LTD
    Inventors: Michel Belley, Denis Deschenes, Rejean Fortin, Jean-Francois Fournier, Sebastien Gagne, Yves Gareau, Jacques Yves Gauthier, Lianhai Li, Joel Robichaud, Michel Therien, Geoffrey K. Tranmer, Zhaoyin Wang
  • Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
    Patent number: 7799787
    Abstract: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: September 21, 2010
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Denis Deschenes, Rejean Fortin, Chun Sing Li, Renata M. Oballa, Yeeman K. Ramtohul
  • SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY
    Publication number: 20100179173
    Abstract: Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome.
    Type: Application
    Filed: June 26, 2008
    Publication date: July 15, 2010
    Inventors: Daniel Guay, Christian Beaulieu, Michel Belley, Sheldon N. Crane, Jeancarlo De Luca, Rejean Fortin, Yves Gareau, Lianhai Li, Michel Therien, Geoffrey K. Tranmer, Vouy Linh Truong, Zhaoyin Wang
  • BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
    Publication number: 20100152208
    Abstract: Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I).
    Type: Application
    Filed: May 22, 2008
    Publication date: June 17, 2010
    Inventors: Serge Leger, Denis Deschenes, Rejean Fortin, Elise Isabel, David Powell
  • Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
    Publication number: 20090088431
    Abstract: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.
    Type: Application
    Filed: December 18, 2006
    Publication date: April 2, 2009
    Inventors: Denis Deschenes, Rejean Fortin, Chun Sing Li, Renata M. Oballa, Yeeman K. Ramtohul
  • Quinolinones as prostaglandin receptor ligands
    Patent number: 7348433
    Abstract: This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or condition
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: March 25, 2008
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Denis Deschenes, Rejean Fortin, Yves Girard
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 7060715
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: June 13, 2006
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Quinolinones as prostaglandin receptor ligands
    Publication number: 20050222194
    Abstract: This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or condition.
    Type: Application
    Filed: December 11, 2002
    Publication date: October 6, 2005
    Inventors: Daniel Dube, Denis Deschenes, Rejean Fortin, Yves Girard
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Publication number: 20050009875
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Application
    Filed: August 11, 2004
    Publication date: January 13, 2005
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Gauthier
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6812346
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: November 2, 2004
    Assignee: Merck Frosst Canada and Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Publication number: 20040029921
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: March 24, 2003
    Publication date: February 12, 2004
    Applicant: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6596736
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Publication number: 20030065011
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 3, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Patent number: 6498151
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 24, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Publication number: 20020091104
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: March 21, 2001
    Publication date: July 11, 2002
    Inventors: Chung Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6071936
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: June 6, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier